Background Over the past decades, US Congress enabled the US Food and Drug
Administration (FDA) to facilitate and expedite drug development for serious conditions …

(1) Background: Any disturbance in the pharmaceutical supply chain (PSC) can disrupt the
supply of medicines and affect the efficiency of health systems. Due to shortages in the …

Background Clinical development paradigms for cell and gene therapies appear to be
different to those of more conventional treatments: therefore, it is informative to explore this …

Abstract Introduction Curative therapies (CTx) to achieve durable remission of HIV disease
without the need for antiretroviral therapy (ART) are currently being explored. Our objective …

The fundamental aim of healthcare is to improve overall health of the population by
providing state-of-the-art healthcare for individuals at an affordable cost. The foundation for …

The increasing number and high prices of orphan drugs have triggered concern among
patients, payers, and policymakers about the affordability of new drugs approved using the …

Biomedical datasets are often modeled as knowledge graphs (KGs) because they capture
the multi-relational, heterogeneous, and dynamic natures of biomedical systems. KG …

Reaching a diagnosis and its communication are two of the most meaningful events in the
physician–patient relationship. When facing a disease, most of the patients' expectations …

Background We consider two key challenges that early-stage biotechnology firms face in
developing a sustainable financing strategy and a sustainable business model: developing …

Only 5% of orphan diseases have approved drugs, leading to a high demand for new
treatment. As a result, pharmaceutical companies have shifted their focus of drug …